Structure Therapeutics' $GPCR Obesity Drug Shows Promising Results, Shares Surge 55%

Jun 3, 2024, 04:45 PM

Structure Therapeutics announced that its experimental oral GLP-1 obesity drug led to significant weight loss in two mid-stage studies. The drug reduced weight by an average of 6.2%, surpassing Wall Street expectations. As a result, the company's shares experienced a substantial increase, rising by up to 55% on Monday in premarket trading. This development positions Structure Therapeutics, traded under $GPCR, to potentially capture a portion of the growing anti-obesity drug market.